Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint flavour tablets

Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets is a specific drug for the symptomatic treatment of cough , both dry and productive, ideal for those seeking rapid and targeted relief. Its formulation combines two active ingredients: dextromethorphan hydrobromide , known for its sedative action on coughs, and guaifenesin , an effective fluidifying agent that promotes the dissolution of phlegm and the clearing of the airways.

The mint-flavored lozenges offer a pleasant sensation of freshness and are convenient to take anywhere, without the need for water. Each lozenge contains 7.5 mg of dextromethorphan and 55 mg of guaifenesin , a combination designed to act both as a cough suppressant and as a phlegm thinner , making the product suitable for combating the different types of cough that can accompany colds and respiratory tract infections.

Bronchenolo Sedative and Fluidifying is particularly suitable for those who want an effective cough treatment with a practical and pleasant tasting product. The lozenges are ideal for adults and children over 6 years old and are a convenient solution to always carry with you. Thanks to the presence of mint flavor , the product leaves the mouth fresh and helps soothe throat irritation.

Choose Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored lozenges for rapid relief from cough , both dry and productive, and to promote the fluidification of phlegm, improving breathing and the well-being of the airways. Available in the best online pharmacies , it is a reliable and quality solution for respiratory well-being.

ACTIVE INGREDIENTS

Active ingredients contained in Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - What is the active ingredient in Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets?

100 ml of syrup contain: • active ingredients : dextromethorphan hydrobromide 0.15 g and guaifenesin 1.00 g. Excipients with known effects : sucrose 73.50 g, propyl parahydroxybenzoate 0.025 g, methyl parahydroxybenzoate 0.075 g, ethyl alcohol 5.00 g. One tablet contains: • active ingredients : dextromethorphan hydrobromide 7.5 mg and guaifenesin 55 mg. Excipients with known effects : sucrose 2080.92 mg, aspartame (E951) 23 mg. For the full list of excipients, see section 6.1.

EXCIPIENTS

Composition of Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - What does Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets contain?

BRONCHENOLO SEDATIVE AND FLUIDIFYING syrup 100 ml of syrup contain: mountain pine essential oil; citric acid monohydrate; alcohol; glycerol; sucrose; sweet orange essence; propyl parahydroxybenzoate; methyl parahydroxybenzoate; sodium saccharin; purified water. BRONCHENOLO SEDATIVE AND FLUIDIFYING mint-flavored lozenges One 2.3 g lozenge of BRONCHENOLO SEDATIVE AND FLUIDIFYING mint-flavored contains: mountain pine essential oil; magnesium trisilicate; aspartame; magnesium stearate; sucrose; mint flavor.

DIRECTIONS

Therapeutic indications Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - Why is Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets used? What is it for?

Symptomatic treatment of cough.

CONTRAINDICATIONS AND SIDE EFFECTS

Contraindications Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - When should Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets not be used?

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. Children under 6 years of age. Patients who are taking or have taken in the last two weeks monoamine oxidase inhibitor (MAOI) antidepressants (see section 4.5). Patients with respiratory insufficiency or at risk of developing respiratory insufficiency (for example, patients with chronic obstructive airways disease or pneumonia, patients with an ongoing asthma attack or exacerbation of asthma).

DOSAGE

Quantity and method of taking Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - How do you take Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets?

Dosage Syrup Adults (including the elderly): 2 teaspoons (10 ml) 2-4 times a day, up to a maximum of 8 teaspoons (40 ml) a day. Paediatric population Children over 12 years : 2 teaspoons (10 ml) 2-4 times a day, up to a maximum of 8 teaspoons (40 ml) a day. Children from 6 to 12 years : 1 teaspoon (5 ml) 3-4 times a day, up to a maximum of 4 teaspoons (20 ml) a day. Administer the medicine every 4-6 hours as needed. Lozenges Adults (including the elderly): 3-6 lozenges a day to dissolve in the mouth, up to a maximum of 6 lozenges a day. Paediatric population Children over 12 years : 3-6 lozenges a day to dissolve in the mouth, up to a maximum of 6 lozenges a day. Children 6 to 12 years : 2-3 lozenges per day to dissolve in the mouth, up to a maximum of 3 lozenges per day. Administer the medicine every 4-6 hours as needed. Method of administration To be administered orally only. Do not exceed the recommended doses.

CONSERVATION

Storage Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - How do you store Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets?

None

WARNINGS

Warnings Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint flavoured tablets - About Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint flavoured tablets it is important to know that:

In the following cases BRONCHENOLO SEDATIVO E FLUIDIFICANTE should be used only after careful medical evaluation: - chronic or persistent cough, such as that which occurs in asthma or emphysema; - severe hepatic insufficiency; - severe renal insufficiency; - concomitant use of selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants (see section 4.5). The patient should be advised to consult a doctor if the cough persists, or if it is accompanied by high fever, skin rash or persistent headache. Do not exceed the maximum recommended dose or frequency of administration. After 5-7 days of treatment without appreciable results, a clinical evaluation is necessary. The concomitant use of other cough and cold medicines should be avoided. The concomitant use of alcohol should be avoided during therapy with BRONCHENOLO SEDATIVO E FLUIDIFICANTE. Cases of abuse and dependence of dextromethorphan have been reported. Particular caution is recommended with adolescents and young adults, as well as with patients with a history of drug or psychoactive substance abuse. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. Approximately 10% of the population is a slow metaboliser of CYP2D6. Exaggerated and/or prolonged effects of dextromethorphan may occur in poor metabolisers and patients with concomitant use of CYP2D6 inhibitors. Caution is therefore necessary in patients who are poor metabolisers of CYP2D6 or who use CYP2D6 inhibitors (see also section 4.5). Risks arising from concomitant use of sedative medicines such as benzodiazepines or related drugs. Concomitant use of BRONCHENOLO SEDATIVE AND FLUIDIFICANTE and sedative medicines such as benzodiazepines, or related drugs, may cause sedation, respiratory depression, as well as death. Because of these risks, concomitant prescribing with sedative medicinal products should be reserved for patients for whom alternative treatment options are not available. If BRONCHENOLO SEDATIVE AND FLUIDIFICANTE is prescribed concomitantly with sedative medicinal products, the lowest effective dose should be used, and the duration of treatment should be as short as possible. Patients should be carefully monitored for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers in order to make them aware of these symptoms (see section 4.5). Serotonin syndrome Serotonergic effects, including the development of a potentially life-threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs), drugs which impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs]) and CYP2D6 inhibitors. Serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities and/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with BRONCHENOLO SEDATIVE AND FLUIDIFICANTE should be discontinued. Paediatric population Serious adverse events, including neurological disorders, may occur in children in case of overdose. Caregivers should be advised not to exceed the recommended dose. Information on excipients with known effects BRONCHENOLO SEDATIVE AND FLUIDIFICANTE syrup contains: • sucrose. Contains 7.35 g of sucrose (sugar) per 10 ml dose. This should be taken into consideration in patients with diabetes mellitus. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine; • ethyl alcohol. This medicine contains 480 mg of alcohol (ethanol) in each 10 ml dose. The amount in 10 ml of this medicine is equivalent to 12 ml of beer and 5 ml of wine. May be harmful for alcoholics. To be taken into consideration in pregnant or breast-feeding women, children and high-risk groups such as people with liver disease or epilepsy. A 10ml dose of this medicine given to a child aged 12 years and weighing less than or equal to 32kg would result in an exposure of 15mg which may cause an increase in blood alcohol concentration (BAC) of approximately 2.5mg/100ml. Co-administration with medicinal products containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, particularly in young children with low or immature metabolic activity. • propyl and methyl parahydroxybenzoates, which may cause allergic reactions (possibly delayed); • Sodium. This medicine contains less than 1 mmol sodium (23mg), i.e. essentially "sodium-free". BRONCHENOLO SEDATIVE AND FLUIDIFICANTE mint flavour lozenges contain: • sucrose. Contains 2.08g sucrose per dose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine; • aspartame. This medicine contains 23 mg aspartame per tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria, a rare genetic disorder in which the amount of phenylalanine builds up because the body cannot process it properly.

INTERACTIONS

Interactions Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - Which medicines or foods can modify the effect of Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets?

The medicinal product should not be used concomitantly with or within 2 weeks of treatment with monoamine oxidase inhibitor (MAOI) antidepressants, as serious adverse reactions, including serotonin syndrome, have been reported (see section 4.3). Patients should be advised to consult their doctor before taking dextromethorphan in combination with the following drugs: - concomitant use of dextromethorphan with selective serotonin reuptake inhibitor antidepressants or tricyclic antidepressants may cause serotonin syndrome with mental status changes, hypertension, agitation, myoclonus, hyperreflexia, diaphoresis, chills and tremors (see section 4.4); - concomitant use of dextromethorphan and alcohol may increase the CNS depressant effects of both substances. CYP2D6 inhibitors Dextromethorphan is metabolised by CYP2D6 and has extensive first-pass metabolism. Concomitant use of potent inhibitors of the CYP2D6 enzyme may increase dextromethorphan concentrations in the body to levels several times higher than normal. This increases the patient's risk of toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhea, and respiratory depression) and the development of serotonin syndrome. Potent inhibitors of CYP2D6 are fluoxetine, paroxetine, quinidine, and terbinafine. When used concomitantly with quinidine, plasma concentrations of dextromethorphan are increased up to 20-fold, resulting in increased adverse effects on the central nervous system of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine, and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dose of dextromethorphan may need to be reduced. The combination with phenylpropanolamine should be used with caution in patients with hypertension, heart disease, diabetes, peripheral vascular disease, prostatic hypertrophy and glaucoma. Treatment with guaifenesin may cause false positive urinary vanillylmandelic acid results. Sedative medicines such as benzodiazepines or related drugs Concomitant use of opioids and sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dosage and duration of concomitant treatment should be limited (see section 4.4).

SIDE EFFECTS

Like all medicines, Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored lozenges can cause side effects - What are the side effects of Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored lozenges?

Data from clinical studies The adverse events reported below have been observed in clinical studies and are considered uncommon adverse reactions (i.e. occurring in ≥1/1000 to <1/100 patients). Adverse reactions are listed according to MedDRA classification. Nervous system disorders • somnolence. Ear and labyrinth disorders • vertigo. Gastrointestinal disorders • gastrointestinal disorder; • nausea; • vomiting; • abdominal discomfort. Post-marketing data The adverse reactions identified during post-marketing use are listed below. Since these reactions are reported voluntarily from a population of uncertain size, their frequency is not known, but is probably very rare (occurring in <1/10000 patients). Nervous system disorders • serotonin syndrome. Serotonin syndrome (with mental status changes, agitation, myoclonus, hyperreflexia, diaphoresis, chills, tremors and hypertension) has been reported with concomitant use of dextromethorphan with antidepressants (monoamine oxidase inhibitors or serotonin reuptake inhibitors) (see sections 4.3 and 4.5). Immune system disorders • hypersensitivity (e.g. rash, urticaria, angioedema). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at - www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

OVERDOSE

Overdose Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets - What are the risks of Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored tablets in case of overdose?

Signs and symptoms Dextromethorphan overdose may be associated with nausea, vomiting, dystonia, agitation, confusion, drowsiness, stupor, nystagmus, cardiotoxicity (tachycardia, abnormal ECG including QTc prolongation), ataxia, toxic psychosis with visual hallucinations, hyperexcitability. In case of massive overdose, the following symptoms may be observed: coma, respiratory depression and convulsions. If taken in excessive quantities, guaifenesin may cause renal calculosis. Management: Activated charcoal may be administered to asymptomatic patients who have ingested dextromethorphan overdoses within the previous hour. Emergency measures include emptying the stomach and supporting vital functions, particularly in order to control respiratory depression and other central nervous system disorders. For patients who have ingested dextromethorphan and are sedated or comatose, naloxone may be considered, in doses usual for the treatment of opioid overdose. Benzodiazepines may be used for seizures and benzodiazepines and external cooling measures for serotonin syndrome hyperthermia.

PREGNANCY AND BREASTFEEDING

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavoured tablets.

There are no data available on pregnancy and breastfeeding. In pregnant and breastfeeding women, the medicine should be administered only in case of real need and under the direct supervision of a doctor.

DRIVING AND USE OF MACHINERY

Taking Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored lozenges before driving or using machinery - Does Bronchenolo Sedative and Fluidifying 7.5 mg + 55 mg 20 mint-flavored lozenges affect driving or using machinery?

BRONCHENOL SEDATIVE AND FLUIDIFYING may alter the ability to drive vehicles and use machinery as it may induce drowsiness or dizziness. Those who may drive motor vehicles or carry out operations requiring a high level of alertness must take this into account.